Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

Annachiara Uccellatore, Stefano Genovese, Ilaria Dicembrini, Edoardo Mannucci, Antonio Ceriello

Research output: Contribution to journalArticlepeer-review


Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.

Original languageEnglish
Pages (from-to)239-256
Number of pages18
JournalDiabetes Therapy
Issue number3
Publication statusPublished - Sep 26 2015


  • GLP-1 RAs
  • Glucagon-like peptide-1 receptor agonists
  • Incretin
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine


Dive into the research topics of 'Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists'. Together they form a unique fingerprint.

Cite this